SV-BR-1-GM, a Clinically Effective GM-CSF-Secreting Breast Cancer Cell Line, Expresses an Immune Signature and Directly Activates CD4+ T Lymphocytes

SV-BR-1-GM, a Clinically Effective GM-CSF-Secreting Breast Cancer Cell Line, Expresses an Immune Signature and Directly Activates CD4+ T Lymphocytes

Targeted cancer immunotherapy with irradiated, granulocyte–macrophage colony-stimulating factor (GM-CSF)-secreting, allogeneic cancer cell lines has been an effective approach to reduce tumor burden in several patients. It is generally assumed that to be effective, these cell lines need to express i...

Full description

Bibliographic Details
Main Authors: Markus D. Lacher, Gerhard Bauer, Brian Fury, Sanne Graeve, Emily L. Fledderman, Tye D. Petrie, Dane P. Coleal-Bergum, Tia Hackett, Nicholas H. Perotti, Ying Y. Kong, William W. Kwok, Joseph P. Wagner, Charles L. Wiseman, William V. Williams
Format: Article
Language:English
Published: Frontiers Media S.A. 2018-05-01
Series:Frontiers in Immunology
Subjects:
SV-BR-1-GM
GVAX
targeted immunotherapy
whole-cell vaccine
therapeutic cancer vaccine
antigen-presenting cells
Online Access:http://journal.frontiersin.org/article/10.3389/fimmu.2018.00776/full

Internet

http://journal.frontiersin.org/article/10.3389/fimmu.2018.00776/full

Similar Items